BACKGROUND: There are no standardized diagnostic or treatment guidelines for patients with advanced unilateral retinoblastoma. MATERIALS AND METHODS: Patients with advanced unilateral retinoblastoma were prospectively treated after enucleation using a risk-based protocol. Patients were assigned to low risk (LR), intermediate risk (IR), or high risk (HR) based on pathology. LR patients underwent observation. IR patients received 4 courses of chemotherapy with vincristine, doxorubicin, and cyclophosphamide (VDC). In the HR group, patients received 3 courses of VDC alternating with 3 courses of vincristine, carboplatin, and etoposide (VCE) and irradiation when indicated. RESULTS: Fifty patients with advanced unilateral retinoblastoma were treated (LR, n=36; IR, n=7; HR, n=7). All eyes were Reese-Ellsworth group V. All bone scans (n=81), lumbar punctures (n=16), and bone marrow aspirates (n=16) were negative. Chemotherapy was well tolerated. Grades 3/4 hematologic toxicities were seen in all patients; grades 3/4 nonhematologic toxicities were seen in half the patients. Only one patient in the HR group received radiation therapy. All patients were alive at the time of analysis with no signs of disease recurrence. Median follow-up was 3.4 years (range, 0.8 to 6.4 y). CONCLUSIONS: Patients with nonmetastatic unilateral retinoblastoma undergoing primary enucleation can be cured with a graduated intensity approach based on pathology.
BACKGROUND: There are no standardized diagnostic or treatment guidelines for patients with advanced unilateral retinoblastoma. MATERIALS AND METHODS:Patients with advanced unilateral retinoblastoma were prospectively treated after enucleation using a risk-based protocol. Patients were assigned to low risk (LR), intermediate risk (IR), or high risk (HR) based on pathology. LR patients underwent observation. IR patients received 4 courses of chemotherapy with vincristine, doxorubicin, and cyclophosphamide (VDC). In the HR group, patients received 3 courses of VDC alternating with 3 courses of vincristine, carboplatin, and etoposide (VCE) and irradiation when indicated. RESULTS: Fifty patients with advanced unilateral retinoblastoma were treated (LR, n=36; IR, n=7; HR, n=7). All eyes were Reese-Ellsworth group V. All bone scans (n=81), lumbar punctures (n=16), and bone marrow aspirates (n=16) were negative. Chemotherapy was well tolerated. Grades 3/4 hematologic toxicities were seen in all patients; grades 3/4 nonhematologic toxicities were seen in half the patients. Only one patient in the HR group received radiation therapy. All patients were alive at the time of analysis with no signs of disease recurrence. Median follow-up was 3.4 years (range, 0.8 to 6.4 y). CONCLUSIONS:Patients with nonmetastatic unilateral retinoblastoma undergoing primary enucleation can be cured with a graduated intensity approach based on pathology.
Authors: L C Moscinski; T W Pendergrass; A Weiss; E Hvizdala; K S Buckley; R E Kalina Journal: J Pediatr Hematol Oncol Date: 1996-05 Impact factor: 1.289
Authors: Santosh G Honavar; Arun D Singh; Carol L Shields; Anna T Meadows; Hakan Demirci; Jacqueline Cater; Jerry A Shields Journal: Arch Ophthalmol Date: 2002-07
Authors: Guillermo Chantada; Adriana Fandiño; María T G Dávila; Julio Manzitti; Elsa Raslawski; Sandra Casak; Enrique Schvartzman Journal: Cancer Date: 2004-02-15 Impact factor: 6.860
Authors: Roger S Riley; Thomas F Hogan; Dawn R Pavot; Robert Forysthe; Davis Massey; Eileen Smith; Lou Wright; Jonathan M Ben-Ezra Journal: J Clin Lab Anal Date: 2004 Impact factor: 2.352
Authors: Viviana E Laurent; Claudia Sampor; Verónica Solernou; Jorge Rossi; Mariano Gabri; Silvia Eandi-Eberle; Maria T G de Davila; Daniel F Alonso; Guillermo L Chantada Journal: Eur J Cancer Date: 2013-05-27 Impact factor: 9.162
Authors: Jonathan W Kim; Sona N Shah; Sarah Green; John O'Fee; Benita Tamrazi; Jesse L Berry Journal: Acta Ophthalmol Date: 2019-08-17 Impact factor: 3.761
Authors: Verónica Pérez; Claudia Sampor; Guadalupe Rey; Andreu Parareda-Salles; Katherine Kopp; Agustín P Dabezies; Gustavo Dufort; Marta Zelter; Juan P López; Marcelo Urbieta; Elisa Alcalde-Ruiz; Jaume Catala-Mora; Mariona Suñol; Diego Ossandon; Adriana C Fandiño; J Oscar Croxatto; María T G de Dávila; Gregory Reaman; Yaddanapudi Ravindranath; Guillermo L Chantada Journal: JAMA Ophthalmol Date: 2018-07-01 Impact factor: 7.389
Authors: Rachel C Brennan; Ibrahim Qaddoumi; Catherine A Billups; Tracy Kaluzny; Wayne L Furman; Matthew W Wilson Journal: Pediatr Blood Cancer Date: 2016-07-13 Impact factor: 3.167
Authors: Jessica Sparrow; Rachel Brennan; Shenghua Mao; Kirsten K Ness; Carlos Rodriguez-Galindo; Matthew Wilson; Ibrahim Qaddoumi Journal: J Pediatr Rehabil Med Date: 2016-05-31
Authors: Rachel C Brennan; Ibrahim Qaddoumi; Shenghua Mao; Jianrong Wu; Catherine A Billups; Clinton F Stewart; Mary Ellen Hoehn; Carlos Rodriguez-Galindo; Matthew W Wilson Journal: J Clin Oncol Date: 2016-10-31 Impact factor: 44.544
Authors: Victoria W Willard; Ibrahim Qaddoumi; Hui Zhang; Lu Huang; Kathryn M Russell; Rachel Brennan; Matthew W Wilson; Carlos Rodriguez-Galindo; Sean Phipps Journal: Pediatr Blood Cancer Date: 2016-11-03 Impact factor: 3.167
Authors: Helen Dimaras; Timothy W Corson; David Cobrinik; Abby White; Junyang Zhao; Francis L Munier; David H Abramson; Carol L Shields; Guillermo L Chantada; Festus Njuguna; Brenda L Gallie Journal: Nat Rev Dis Primers Date: 2015-08-27 Impact factor: 52.329
Authors: Victoria W Willard; Ibrahim Qaddoumi; Haitao Pan; Chia-Wei Hsu; Rachel C Brennan; Matthew W Wilson; Carlos Rodriguez-Galindo; Kristin Goode; Kendra Parris; Sean Phipps Journal: J Clin Oncol Date: 2021-04-23 Impact factor: 50.717